Navigation Links
Mylan Announces Settlement Agreement for Namenda®
Date:7/22/2010

PITTSBURGH, July 22 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into settlement and license agreements with Forest Laboratories and Merz Pharmaceuticals related to Namenda® Tablets, 5 mg and 10 mg, known generically as Memantine Hydrochloride (HCl) Tablets.

Pursuant to the settlement and license agreements, Mylan will have the right to market Memantine HCl in the U.S. on Jan. 11, 2015, or earlier, under certain circumstances. Namenda had U.S. sales of $1.2 billion for the twelve months ending March 31, 2010, according to IMS Health. Additional details of the agreement remain confidential and remain subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Currently, Mylan has 131 ANDAs pending FDA approval representing $92.1 billion in annual brand sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $21.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2009 according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement and marketing of the product. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
2. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
3. Mylan Receives Approval for Nabumetone Tablets
4. Mylan Schedules Second Quarter 2010 Financial Results Conference Call and Live Webcast
5. Mylan Receives Approval for Generic Version of Arimidex® Tablets
6. Mylan Receives Approval for Generic Version of Zocor® Tablets
7. Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets
8. Mylan Receives Approval for Generic Version of Neurontin® Tablets
9. Mylan Receives Approval for Generic Version of Valtrex®
10. Mylan Launches Temazepam Capsules USP, 7.5 mg
11. Mylan Announces Completion of Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ViewRay, Inc. (Nasdaq: VRAY) announced today that the German Research ... Germany , has purchased a MRIdian Linac ... Heidelberg as part of its initiative for MRI-based radiation ... headed by Medical Director and Professor Jürgen Debus, M.D., ... Cancer Research Center (DKFZ), the Heidelberg Heavy Ion Center ...
(Date:1/19/2017)... New Review of Safinamide ... Symptoms and Motor Complications in Mid- to Late-stage ... ... C Warren Olanow ... 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published ...
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
Breaking Medicine Technology:
(Date:1/19/2017)... Beach, CA (PRWEB) , ... January 19, 2017 ... ... Oral Health, is now offering treatments for patients with sleep apnea and TMJ ... consequences for dental and physical health. Dr. Rassouli provides personalized care to reduce ...
(Date:1/19/2017)... PA (PRWEB) , ... January 19, 2017 , ... Allegheny ... experience of patients who seek access to the Network’s programs and services in the ... primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a family ... Virginia region, is inaugurating a charity event to honor Chad Phillip Dermyer, a local ... last year, Chad Phillip Dermyer and his fellow officers were conducting routine stops of ...
(Date:1/19/2017)... Antonio, TX (PRWEB) , ... January 19, 2017 , ... ... has for the fifth consecutive year donated money to the Triumph Over Kid Cancer ... A. Ragan was one of those children. James saw firsthand the effect of the ...
(Date:1/19/2017)... CA (PRWEB) , ... January 18, 2017 , ... The ... while driving during a rain storm by slowing down and increasing the space between ... Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain ...
Breaking Medicine News(10 mins):